878 Safety and Efficacy of the Ultrathin Orsio Sirolimus-Eluting Stent use in ST-Elevation Myocardial Infarct. An Analysis From a Large Australian Regional Centre

Abstract

We aim to review the real-world safety and efficacy of the Orsiro stent in STEMI population in Wollongong Hospital. We are a large tertiary centre with an extensive catchment area attending 75 STEMI per year on average. The Orsiro sirolimus-eluting stent is designed with ultrathin struts and biodegradable polymer, conferring potential favourable clinical outcomes. Recent meta-analysis comparing Orsiro stent against contemporary DES showed similar outcomes with trend toward lesser target lesion failure (TLF) and MI. We analysed 75 STEMI patients receiving 117 Orsiro stents in total from April 2019 to January 2020. Our analysis group entailed 20 female (25.6%) and 56 male (74.4%) patients, 65 primary PCI (83.3%) and 13 rescue PCI (16.7%). Target lesions encompassed 61 RCA (52.1%), 32 LAD (27.4%), 20 LCx (17.1%) and 4 LMCA (3.4%). Mean stent diameter was 3.04mm and mean stent length was 21.8mm. The primary endpoint was TLF, target lesion revascularization (TLR) and definite stent thrombosis at 3 months. Secondary endpoints were death of all cause, stroke, and major bleeding at 3 months. At 3 months, there was 1 of 78 (1.3%) definite stent thrombosis, 1 major bleeding and 1 stroke. There were 5 all-cause deaths from 7 out-of-hospital cardiac arrests. The primary finding showed Orsiro stent has low rate of MACE with low rate of TLF, TLR and definite stent thrombosis. Further analysis of long-term outcomes from Osiro stent in this high-risk group would be highly informative, and we will continue analysing data in this subgroup population.